BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 756K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

22 articles for SL Posy

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Dimeric Macrocyclic Antagonists of Inhibitor of Apoptosis Proteins for the Treatment of Cancer.EBI
Bristol-Myers Squibb Research
The discovery of macrocyclic XIAP antagonists from a DNA-programmed chemistry library, and their optimization to give lead compounds with in vivo antitumor activity.EBI
Ensemble Therapeutics
Discovery of Two Novel Antiplatelet Clinical Candidates (BMS-986120 and BMS-986141) That Antagonize Protease-Activated Receptor 4.EBI
Bristol-Myers Squibb Research & Early Development
Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).EBI
Biocon Bristol Myers Squibb Research Center (Bbrc)
Discovery of Non-Nucleotide Small-Molecule STING Agonists EBI
Bristol Myers Squibb Research and Development
Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).EBI
Princ
Discovery of Potent Protease-Activated Receptor 4 Antagonists with in Vivo Antithrombotic Efficacy.EBI
Bristol-Myers Squibb Research & Development
Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereofBDB
Chia Tai Tianqing Pharmaceutical Group
DEUTERATED DHODH INHIBITORSBDB
Immunic
Preparation for 6-amino-1H-pyrazolo[3,4-d]pyrimidine-based JAK kinase inhibitor and application thereofBDB
Peking Union Medical College
Compounds for the treatment of BRAF-associated diseases and disordersBDB
Array Biopharma
Formulations of Tie-2 activators and methods of use thereofBDB
Eyepoint Pharmaceuticals
KDM5 inhibitorsBDB
Merck Sharp & Dohme
JAK kinase inhibitor compounds for treatment of respiratory diseaseBDB
Theravance Biopharma R&D Ip
Substituted pyrazolo/imidazolo bicyclic compounds as PDE2 inhibitorsBDB
Merck Sharp & Dohme
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereofBDB
Enanta Pharmaceuticals
The inhibition study of human UDP-glucuronosyltransferases with cytochrome P450 selective substrates and inhibitors.BDB
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Stereoselective inhibition of butyrylcholinesterase by enantiomers of exo- and endo-2-norbornyl-N-n-butylcarbamates.BDB
Chung Shan Medical University Hospital
Evaluation of 2-indolcarbohydrazones as potent a-glucosidase inhibitors, in silico studies and DFT based stereochemical predictions.BDB
Universiti Teknologi Mara (Uitm)
Substituted pyrrolidine-2-carboxamidesBDB
F. Hoffmann-La Roche
Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.BDB
Eli Lilly